BOSTON and LONDON, July 10, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals
plc (http://www.centessa.com/) (Nasdaq: CNTA), a clinical-stage pharmaceutical
company focused on discovering and developing medicines that are
transformational for patients, today announced the dosing of the first subject
in its registrational PRESent-2 study of SerpinPC for the treatment of
hemophilia B without inhibitors. The dosing phase of PRESent-2 follows a minimum
12-week observation period during which prospective baseline data of the
subject's disease status under their current therapy are collected to support
regulatory review of the benefit and risk profile of SerpinPC. SerpinPC is an
investigational subcutaneously administered novel inhibitor of activated protein
C (APC) being developed as a potential treatment for hemophilia B, with or
without inhibitors.
"There remains a significant global need for new treatment options for persons
with hemophilia B," said Antoine Yver MD MSc, Chairman of Development of
Centessa. "Based on encouraging clinical data from our ongoing Phase 2a study,
we believe SerpinPC has the potential to be a first-in-class subcutaneously
administered therapy with a differentiated safety profile for persons with
hemophilia B, subject to regulatory review and approval. We are excited to be
evaluating the potential of SerpinPC's novel mechanism of action in the
registrational PRESent-2 study. We expect to enroll and dose additional patients
across our clinical trial sites and advance toward the interim analysis planned
when 36 subjects reach 12 weeks on treatment in Part 1 of the study."
The PRESent-2 study (AP-0102) is a Phase 2b, global, open-label, seamless
adaptive design study to investigate the efficacy and safety of subcutaneous
dosing of SerpinPC every week, every 2 weeks, or every 4 weeks in approximately
120 adult (aged 18 to =12 to Â